Atossa Therapeutics, Quantum Leap Healthcare Provide Enrollment Update For (Z)-Endoxifen Arm Of Ongoing I-SPY 2 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics and Quantum Leap Healthcare have provided an enrollment update for the (Z)-Endoxifen arm of the ongoing I-SPY 2 clinical trial. The trial is currently in progress.
June 28, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Atossa Therapeutics is involved in the ongoing I-SPY 2 clinical trial. The recent update on enrollment could impact investor sentiment.
The news about the enrollment update for the (Z)-Endoxifen arm of the ongoing I-SPY 2 clinical trial directly involves Atossa Therapeutics. This could potentially influence investor sentiment, although the exact impact is uncertain without more specific details about the update.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100